Eisai’s Oral Aloxi Approved For Chemo-related Nausea/Vomiting
This article was originally published in The Pink Sheet Daily
Executive Summary
Antiemetic gained through MGI acquisition competes with oral therapies Zofran from GSK and Roche’s Kytril .
You may also be interested in...
Aloxi GMP Problems May Trigger Import Controls
France's Pierre Fabre Medicament Production could find the antiemetic it manufactures for Eisai is barred from the U.S. until it takes corrective action on manufacturing problems.
Aloxi GMP Problems May Trigger Import Controls
France's Pierre Fabre Medicament Production could find the antiemetic it manufactures for Eisai is barred from the U.S. until it takes corrective action on manufacturing problems.
Eisai Wins Post-Operative Indication For Antiemetic Aloxi
Gained through the acquisition of MGI Pharma, drug adds indication for post-operative nausea and vomiting.